Skip to main content
Clinical Trials/NCT05970328
NCT05970328
Completed
Not Applicable

HMS ECG Clinical Validation Study - Protocol External Site

Carré Technologies Inc.2 sites in 1 country75 target enrollmentJuly 24, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cardiac Rhythm Disturbance
Sponsor
Carré Technologies Inc.
Enrollment
75
Locations
2
Primary Endpoint
ECG characteristics measurement agreement
Status
Completed
Last Updated
last year

Overview

Brief Summary

The goal of this observational study is to validate the efficacy of the Hexoskin Medical System (HMS) for its intended use (i.e., manual assessment of cardiac rhythm disturbances) in non-critical adult participants who are suspected of having an arrhythmia or have evidence of arrhythmia requiring monitoring via 24-hour Holter monitor.

Detailed Description

The main questions it aims to answer are: 1. Whether the HMS ECG recordings can be used to accurately detect cardiac beats when compared with the Holter monitor 2. Whether there are good agreements between the HMS and Holter monitor in ECG characteristics 3. Whether the HMS ECG recordings can be used to accurately classify cardiac rhythm/rhythm disturbance when compared with the Holter monitor 4. What is the accuracy of using HMS ECG recordings to detect cardiac beats 5. What is the accuracy of using HMS ECG recordings to identify cardiac rhythm/rhythm disturbance Participants will wear the HMS and the Holter monitor at the same time to record ECG signals. Researchers will evaluate the ECG recordings acquired from both devices and assess the above questions.

Registry
clinicaltrials.gov
Start Date
July 24, 2023
End Date
February 17, 2024
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Carré Technologies Inc.
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Provision of signed and dated informed consent form.
  • Stated willingness to comply with all study procedures and availability for the duration of the study.
  • Male or female, aged 21 years or older.
  • Participants must be suspected of having an arrhythmia or have evidence of arrhythmia requiring monitoring via 24-hour Holter monitor.

Exclusion Criteria

  • Body circumference that is not covered by the HMS Shirt sizing chart
  • Presence of pacemaker or Implantable Cardioverter-Defibrillator (ICD) devices
  • Known allergic reactions to silver or polyamide/polyester/elastane
  • Known allergic reactions to ECG gel electrodes
  • Documented medical condition or illness requiring intensive medical treatment or care

Outcomes

Primary Outcomes

ECG characteristics measurement agreement

Time Frame: 2 days

The agreement (Bland-Altman plots) of Holter monitor(reference standard) and HMS to measure each of the four (4) ECG Characteristics. ECG characteristics measured in this study include: RR Interval (ms), PR Interval (ms), PP Interval (ms), and QRS Duration (ms).

Secondary Outcomes

  • Heart rate agreement(2 days)

Study Sites (2)

Loading locations...

Similar Trials